company background image
SNT logo

Syntara CHIA:SNT Stock Report

Last Price

AU$0.077

Market Cap

AU$123.2m

7D

-2.5%

1Y

n/a

Updated

10 Jan, 2025

Data

Company Financials +

Syntara Limited

CHIA:SNT Stock Report

Market Cap: AU$123.2m

SNT Stock Overview

Operates as a clinical-stage drug development company that focuses on blood-related cancers in Australia. More details

SNT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap (A$123M)

Does not have meaningful revenue (A$6M)

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Syntara Limited Competitors

Vita Life Sciences

ASX:VLS

AU$108.8m

IDT Australia

ASX:IDT

AU$47.3m

Mayne Pharma Group

ASX:MYX

AU$370.5m

Recce Pharmaceuticals

ASX:RCE

AU$110.1m

Price History & Performance

Summary of share price highs, lows and changes for Syntara
Historical stock prices
Current Share PriceAU$0.077
52 Week HighAU$0.085
52 Week LowAU$0.015
Beta0.56
1 Month Change11.59%
3 Month Change79.07%
1 Year Changen/a
3 Year Change-26.67%
5 Year Change-46.90%
Change since IPO10.00%

Recent News & Updates

Recent updates

Shareholder Returns

SNTAU PharmaceuticalsAU Market
7D-2.5%-1.4%1.3%
1Yn/a-8.4%9.5%

Return vs Industry: Insufficient data to determine how SNT performed against the Australian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how SNT performed against the Australian Market.

Price Volatility

Is SNT's price volatile compared to industry and market?
SNT volatility
SNT Average Weekly Movement14.1%
Pharmaceuticals Industry Average Movement10.1%
Market Average Movement8.0%
10% most volatile stocks in AU Market16.7%
10% least volatile stocks in AU Market3.0%

Stable Share Price: SNT's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: SNT's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
199821Gary Phillipssyntaratx.com.au

Syntara Limited operates as a clinical-stage drug development company that focuses on blood-related cancers in Australia. The company’s lead product candidate is SNT-5505, which is in Phase 2 trial to treat myelofibrosis, myelodysplastic syndrome, hepatocellular carcinoma, and pancreatic cancer, as well as scar prevention. It also develops SNT-4728 in Phase 2 trial for the treatment of neurodegenerative diseases comprising isolated rapid eye movement sleep behavior disorder (IRBD) and Parkinson’s disease; SNT-5382, which is a selective lysyl oxidase-like 2 inhibitor in Phase 1 trial to treat chronic fibrosis; and SNT-8370 for the treatment of inflammation.

Syntara Limited Fundamentals Summary

How do Syntara's earnings and revenue compare to its market cap?
SNT fundamental statistics
Market capAU$123.17m
Earnings (TTM)-AU$13.67m
Revenue (TTM)AU$5.76m

21.4x

P/S Ratio

-9.0x

P/E Ratio

Is SNT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SNT income statement (TTM)
RevenueAU$5.76m
Cost of RevenueAU$8.30m
Gross Profit-AU$2.53m
Other ExpensesAU$11.13m
Earnings-AU$13.67m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0087
Gross Margin-43.98%
Net Profit Margin-237.09%
Debt/Equity Ratio0.2%

How did SNT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 02:46
End of Day Share Price 2025/01/10 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Syntara Limited is covered by 12 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dennis HulmeAPP Securities Pty Ltd.
Anubhav SaxenaBell Potter
Thomas WakimBell Potter